Middle East Consensus Sets 25 Statements for Achondroplasia Care and AccessNew Guidelines Improve Care for Children with Achondroplasia
Frontiers in MedicinePublished September 17, 2026DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider this consensus for regional care standards, but note it lacks efficacy and safety data.
This publication is a consensus statement, not a primary trial, developed to guide the management of achondroplasia in the Middle East. It presents 25 consensus statements covering diagnosis, surveillance, multidisciplinary management, psychosocial support, pharmacologic interventions, transition to adult care, and research priorities.
The authors emphasize early detection, long-term outcomes, family support, and equitable access to emerging therapies. The stated goal is to standardize and enhance care quality across the region by integrating international best practices with local healthcare realities.
No comparative effectiveness data, effect sizes, or safety outcomes are reported in the source. The statement does not provide a study population, sample size, or follow-up duration.
Key limitations acknowledged by the authors include delayed diagnosis, inconsistent access to genetic testing, limited multidisciplinary infrastructure, and inequities in treatment availability. These barriers may constrain the practical implementation of the consensus recommendations.
For clinicians, this consensus offers a framework for regional care but does not replace evidence from controlled trials. Practice relevance centers on aligning local care pathways with the recommended standards while accounting for resource limitations.
How this fits prior evidence
This consensus statement extends prior coverage of vosoritide in achondroplasia, which included a systematic review and meta-analysis showing growth gains and injection site reactions, and a single-arm study in prepubertal hypochondroplasia patients. Unlike those reports, this guideline does not present new efficacy or safety data. Instead, it addresses a gap in regional care standardization and equitable access to emerging therapies, including pharmacologic interventions, across the Middle East.
Experts have established a new set of guidelines to improve how achondroplasia is managed in the Middle East. These guidelines cover many parts of care, including early diagnosis, regular medical checkups, and the transition from pediatric to adult care. The goal is to bring international best practices into local healthcare settings.
The guidelines also emphasize the importance of multidisciplinary care. This means involving different types of specialists to provide a complete treatment plan. They also highlight the need for psychosocial support for patients and their families. These steps are designed to provide more consistent and high-quality care for everyone affected by the condition.
There are still some challenges to overcome, such as inconsistent access to genetic testing and limited medical infrastructure in some areas. While the new guidelines provide a roadmap for better care and more equitable access to therapies like vosoritide, patients should talk to their doctors to understand how these standards apply to their specific situation.
What this means for you:
New regional guidelines aim to improve diagnosis, support, and treatment access for people with achondroplasia.
Common questions
What does the new care plan for achondroplasia include?
The new guidelines cover 25 different areas of care. These include early diagnosis, regular medical monitoring, multidisciplinary management, and psychosocial support. They also focus on the transition to adult care and ensuring patients have better access to emerging therapies and research.
What are the main goals of these new guidelines?
The main goal is to standardize and improve the quality of care for people with achondroplasia. By combining international best practices with local healthcare realities, the guidelines aim to provide more consistent support and better access to treatments across the region.
What challenges still exist for patients with achondroplasia?
Some challenges remain, including delayed diagnoses and inconsistent access to genetic testing. There are also concerns regarding limited multidisciplinary infrastructure and inequalities in how some patients can access new medications and treatments.
Achondroplasia is the most common skeletal dysplasia and presents as a lifelong, multi-system condition characterized by disproportionate short stature, rhizomelic limb shortening, macrocephaly with frontal bossing, and a spectrum of neurological, respiratory, orthopedic, and psychosocial complications. Effective management requires anticipatory surveillance, coordinated multidisciplinary care, and early recognition of life-threatening complications. Therapeutic options have expanded in recent years with the introduction of vosoritide, a C-type natriuretic peptide analog that targets the underlying pathophysiology and has demonstrated significant improvements in linear growth and body proportionality in eligible children. However, global advances have not been uniformly translated into clinical practice across the Middle East, where challenges such as delayed diagnosis, inconsistent access to genetic testing, limited multidisciplinary infrastructure, and inequities in treatment availability continue to impact patient outcomes. In this document, a panel of pediatric endocrinologists and clinical geneticists from the Middle East convened to develop a set of regionally relevant, evidence-informed consensus statements on the diagnosis and management of achondroplasia in light of novel advances in the management of this condition. Using a modified Delphi process, the panel achieved consensus on 25 statements covering diagnosis, surveillance, multidisciplinary management, psychosocial support, pharmacologic interventions, transition to adult care, and research priorities. This consensus, endorsed by the Arab Society for Pediatric Endocrinology and Diabetes (ASPED) and the MENA Medical Genetics Association, aims to standardize and enhance the quality of care for individuals with achondroplasia across the region by integrating international best practices with local healthcare realities. The author panel believes that the implementation of these recommendations has the potential to improve early detection, optimize long-term outcomes, strengthen family support, and expand equitable access to emerging therapies.
